Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • ID: 3821702
  • Company Profile
  • 88 pages
  • Global Markets Direct
  • Alnylam Pharmaceuticals Inc
1 of 4
Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

‘Alnylam Pharmaceuticals, Inc. - Product Pipeline Review, 2016’, provides an overview of the Alnylam Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alnylam Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Alnylam Pharmaceuticals, Inc.
- The report provides overview of Alnylam Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Alnylam Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Alnylam Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Alnylam Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alnylam Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alnylam Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Figures

Alnylam Pharmaceuticals, Inc. Snapshot

Alnylam Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Alnylam Pharmaceuticals, Inc. - Research and Development Overview

Key Therapeutic Areas

Alnylam Pharmaceuticals, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Alnylam Pharmaceuticals, Inc. - Pipeline Products Glance

Alnylam Pharmaceuticals, Inc. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Alnylam Pharmaceuticals, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Alnylam Pharmaceuticals, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Alnylam Pharmaceuticals, Inc. - Drug Profiles

patisiran

Product Description

Mechanism of Action

R&D Progress

revusiran

Product Description

Mechanism of Action

R&D Progress

ALN-PCSsc

Product Description

Mechanism of Action

R&D Progress

fitusiran

Product Description

Mechanism of Action

R&D Progress

ALN-AAT

Product Description

Mechanism of Action

R&D Progress

ALN-CC5

Product Description

Mechanism of Action

R&D Progress

ALN-GO1

Product Description

Mechanism of Action

R&D Progress

ALN-HBV

Product Description

Mechanism of Action

R&D Progress

ALN-AS1

Product Description

Mechanism of Action

R&D Progress

ALN-TTRsc02

Product Description

Mechanism of Action

R&D Progress

ALN-VSP

Product Description

Mechanism of Action

R&D Progress

ALN-AC3

Product Description

Mechanism of Action

R&D Progress

ALN-AGT

Product Description

Mechanism of Action

R&D Progress

ALN-ANG

Product Description

Mechanism of Action

R&D Progress

ALN-PDL

Product Description

Mechanism of Action

R&D Progress

ALN-TMP

Product Description

Mechanism of Action

R&D Progress

Antisense RNAi Oligonucleotide to Target Cyclin-Dependent Kinase Inhibitor 1 for Bladder Cancer

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Oncology and Viral Infections

Product Description

Mechanism of Action

R&D Progress

ALN-HDV

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotide for Undisclosed Indication

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotides for Genetic Diseases

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotides for Hepatic Infections

Product Description

Mechanism of Action

R&D Progress

RNAi Oligonucleotides for NASH, Cardiovascular and Metabolic Disorders

Product Description

Mechanism of Action

R&D Progress

Alnylam Pharmaceuticals, Inc. - Pipeline Analysis

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Target

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Route of Administration

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Molecule Type

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action

Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates

Alnylam Pharmaceuticals, Inc. - Dormant Projects

Alnylam Pharmaceuticals, Inc. - Company Statement

Alnylam Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Alnylam Pharmaceuticals, Inc., Key Information

Alnylam Pharmaceuticals, Inc., Key Facts

Alnylam Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Alnylam Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016

Alnylam Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Alnylam Pharmaceuticals, Inc. - Phase III, 2016

Alnylam Pharmaceuticals, Inc. - Phase II, 2016

Alnylam Pharmaceuticals, Inc. - Phase I, 2016

Alnylam Pharmaceuticals, Inc. - Preclinical, 2016

Alnylam Pharmaceuticals, Inc. - Discovery, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Target, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Alnylam Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016

Alnylam Pharmaceuticals, Inc., Subsidiaries 86List of Figures

Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Alnylam Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Alnylam Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll